# PT-141 for Women: The Approved HSDD Indication (Bremelanotide) > PT-141 for women is the one FDA-approved use: acquired, generalized HSDD in premenopausal women, established by the RECONNECT Phase 3 trials. The endpoints, the dosing, and the comparisons, cited. The single use bremelanotide is approved for — acquired, generalized HSDD in premenopausal women — read through the RECONNECT trials, the fMRI mechanism, and the comparison with the alternatives. ## In plain English PT-141 for women is the one use this drug is actually approved for. The condition is HSDD — hypoactive sexual desire disorder, meaning persistent low sexual desire that causes genuine personal distress — and the approval covers it only in women who have not yet reached menopause, and only the "acquired, generalized" form (it came on after a period of normal desire and applies across situations, not just to one partner). Two large trials showed the compound modestly raises desire and lowers the distress, and a brain-scan study showed it changes how the brain responds to sexual cues. The benefit is real but modest, and nausea is the common downside. This page summarizes those findings and is not medical advice. ## What does PT-141 do for women? In premenopausal women with HSDD, bremelanotide modestly increased sexual desire and reduced desire-related distress in the pivotal trials [3]. The mechanistic picture behind that endpoint is well drawn: an fMRI study showed that MC4R agonism increased desire for up to 24 hours and altered how the brain processed erotic stimuli, enhancing amygdala-insula connectivity [5]. A neurobiology review tied the effect to MC4R activation across hypothalamic and limbic circuits [6], and animal work — from selective facilitation of solicitational behavior in female rats to MC4R signaling in Sim1 neurons permitting receptivity in female mice — supplies the circuit-level support [2] [8]. What it does is therefore specific: it acts on the brain's desire circuitry, as needed, in a defined population. What it does not do is act on blood flow, raise testosterone, or work outside the approved group on the strength of the approval [1] [11]. ## The approved scope, stated plainly Bremelanotide is approved for acquired, generalized HSDD in premenopausal women — and nothing else [11]. "Acquired" means the low desire developed after a period of normal function; "generalized" means it is not limited to a specific partner or situation. The FDA approval (NDA 210557, June 21, 2019) rests on the two RECONNECT trials in exactly this population [3] [11]. Everything outside that sentence is off-label. Use in men, use for erectile dysfunction, use in postmenopausal women, and use for general sexual performance are not supported by the approval; the male and erectile evidence is early-phase and investigational only, and this site describes it as such throughout [1]. Stating the boundary plainly is not a hedge — it is the most accurate single thing that can be said about who this drug was actually shown to help. ## What is the PT-141 dosage for women? The label specifies **1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated sexual activity, no more than one dose per 24 hours and no more than eight doses per month** [11]. This is reported as a label finding for premenopausal women with HSDD, not as a protocol for any individual to follow. It is the dose carried from Phase 2 dose-ranging into both RECONNECT trials and the 52-week extension, and the monthly and daily caps reflect the pharmacology rather than convenience [3] [4] [11]. The fuller dosing and pharmacokinetic picture lives on the [PT-141 dosage](/dosage) page. ## How does PT-141 compare to flibanserin and testosterone for women? Three options dominate the conversation about pharmacologic treatment of low desire in women, and they differ on almost every axis. Bremelanotide is an as-needed subcutaneous melanocortin agonist taken before anticipated activity [11]. Flibanserin — the other approved HSDD medication — is a daily oral drug with a different mechanism and a different dosing rhythm. Off-label testosterone therapy is a third approach with its own evidence base and its own regulatory status. A 2025 review of novel pharmacologic treatments of female sexual dysfunction situated bremelanotide among these current and emerging therapies [14], and a 2025 comparative conference abstract contrasted the effect profiles of flibanserin, bremelanotide, and testosterone therapy directly [15]. The honest summary is that these are different tools with different trade-offs — as-needed injection versus daily pill versus hormone therapy — and the literature compares rather than ranks them. This site reports those comparisons; it does not recommend among them. ## How the women in the trials experienced it Patient-reported data complement the endpoints. A patient-experience analysis described how premenopausal women treated with bremelanotide for HSDD perceived its benefits and tolerability, contextualizing the modest trial effect sizes against lived experience [9]. The subgroup analyses found efficacy broadly consistent across demographic and clinical subgroups of the trial population [7], and the long-term extension found the benefit sustained over a year [4]. The tolerability story is inseparable from the benefit story here: nausea was common and the leading reason women discontinued [4]. For the full adverse-event ledger — including the transient blood-pressure signal and the hyperpigmentation — see [PT-141 side effects](/side-effects). Read together, the two pages give the complete picture: a real, modest, brain-mediated benefit in a defined population, bounded by a real tolerability cost. Notes gathered from community discussion — anecdotal, not peer-reviewed, and carrying no citation — frequently describe a brain-led shift in interest rather than a physical one, and frequently flag nausea as the deciding factor in whether women continue. Those impressions are consistent with the cited record above, but they are reported experiences, not evidence, and not advice. --- An after-dark poster reading of the bremelanotide record — the one approved use staged apart from the off-label male research, the modest endpoints set beside the numbers that qualify them, the nausea-led tolerability cost read in full, and the field reports pinned plainly to one side as unverified; no clinic behind the wall, and nothing here dosed, dispensed, or sold.